Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis

Experimental Hematology

Volumn 35, Issue 12, 2007, Pages 1801-1811

  Zhao, Wei Li ^a   Wang, Lan ^a,b   Liu, Yuan Hua ^a   Yan, Jin Song ^a   Leboeuf, Christophe ^c   Liu, Yan Yan ^a   Wu, Wei Li ^a   Janin, Anne ^c   Chen, Zhu ^a,b   Chen, Sai Juan ^a,b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD20 ANTIBODY; HISTONE DEACETYLASE INHIBITOR; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; RITUXIMAB; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DAUDI CELL; DISEASE MODEL; ENZYME ACTIVATION; GENE INACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SURVIVAL TIME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTONE DEACETYLASES; HUMANS; LYMPHOMA, B-CELL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

MURINAE;

EID: 36248959806     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.06.009     Document Type: Article

References (39)

1. Cartron G., Watier H., Golay J., and Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104 (2004) 2635-2642
2. Jazirehi A.R., and Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24 (2005) 2121-2143
3. Alas S., Emmanouilides C., and Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7 (2001) 709-723
4. Jazirehi A.R., Huerta-Yepez S., Cheng G., and Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 65 (2005) 264-276
5. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1 (2001) 194-202
6. Melnick A., and Licht J.D. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol 9 (2002) 322-332
7. O'Connor O.A., Kelly W., Wang E.S., et al. Clinical development of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in aggressive non-Hodgkin's lymphomas (NHL) and Hodgkin's disease. Blood 98 (2001) 611a
8. O'Connor O.A., Heaney M.L., Schwartz L., et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24 (2006) 166-173
9. Koopman G., Reutelingsperger C.P., Kuijten G.A., Keehnen R.M., Pals S.T., and van Oers M.H. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84 (1994) 1415-1420
10. Kano Y., Akutsu M., Tsunoda S., et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97 (2001) 1999-2007
11. Zhao W.L., Daneshpouy M.E., Mounier N., et al. Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood 103 (2004) 695-697
12. He L.Z., Tolentino T., Grayson P., et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108 (2001) 1321-1330
13. Dai Y., Rahmani M., Dent P., and Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 25 (2005) 5429-5444
14. Gillies S.D., Lan Y., Williams S., et al. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 105 (2005) 3972-3978
15. Yang E., and Korsmeyer S.J. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 88 (1996) 386-401
16. Catz S.D., and Johnson J.L. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20 (2001) 7342-7351
17. Chen C., Edelstein L.C., and Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 20 (2000) 2687-2695
18. Klein E., Klein G., Nadkarni J.S., Nadkarni J.J., Wigzell H., and Clifford P. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res 28 (1968) 1300-1310
19. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2 (2002) 301-310
20. Reuther J.Y., and Baldwin Jr. A.S. Apoptosis promotes a caspase-induced amino-terminal truncation of IkappaBalpha that functions as a stable inhibitor of NF-kappaB. J Biol Chem 274 (1999) 20664-20670
21. Barkett M., Xue D., Horvitz H.R., and Gilmore T.D. Phosphorylation of IkappaB-alpha inhibits its cleavage by caspase CPP32 in vitro. J Biol Chem 272 (1997) 29419-29422
22. Mounier N., Briere J., Gisselbrecht C., et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101 (2003) 4279-4284
23. Jazirehi A.R., Gan X.H., De Vos S., Emmanouilides C., and Bonavida B. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2 (2003) 1183-1193
24. Rosato R.R., Almenara J.A., Dai Y., and Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2 (2003) 1273-1284
25. Almenara J., Rosato R., and Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 16 (2002) 1331-1343
26. Xiong Y., Dowdy S.C., Podratz K.C., et al. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res 65 (2005) 2684-2689
27. Kurland J.F., Kodym R., Story M.D., Spurgers K.B., McDonnell T.J., and Meyn R.E. NF-kappaB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene. J Biol Chem 276 (2001) 45380-45386
28. Gilmore T.D., Kalaitzidis D., Liang M.C., and Starczynowski D.T. The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene 23 (2004) 2275-2286
29. Sun S.C., Ganchi P.A., Ballard D.W., and Greene W.C. NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science 259 (1993) 1912-1915
30. Takada Y., Gillenwater A., Ichikawa H., and Aggarwal B.B. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-{kappa}B activation. J Biol Chem 281 (2006) 5612-5622
31. Yu C., Rahmani M., Conrad D., Subler M., Dent P., and Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102 (2003) 3765-3774
32. Yu C., Rahmani M., Almenara J., et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res 63 (2003) 2118-2126
33. Kim K.W., Kim B.J., Chung C.W., et al. Caspase cleavage product lacking amino-terminus of IkappaBalpha sensitizes resistant cells to TNF-alpha and TRAIL-induced apoptosis. J Cell Biochem 85 (2002) 334-345
34. Kim H.S., Chang I., Kim J.Y., Choi K.H., and Lee M.S. Caspase-mediated p65 cleavage promotes TRAIL-induced apoptosis. Cancer Res 65 (2005) 6111-6119
35. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 6 (2005) 827-837
36. Yujiri T., Sather S., Fanger G.R., and Johnson G.L. Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption. Science 282 (1998) 1911-1914
37. Baumann B., Weber C.K., Troppmair J., et al. Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. Proc Natl Acad Sci U S A 97 (2000) 4615-4620
38. Hoffman B., Amanullah A., Shafarenko M., and Liebermann D.A. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21 (2002) 3414-3421
39. Dave S.S., Fu K., Wright G.W., et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354 (2006) 2431-2442